BRAF and melanoma: Based on the ability of MBZ to target both mutant and wild-type BRAF, two patient-derived melanoma cell lines (BAK and BUL) harboring the same BRAFWT/NRASQ61K mutation profile and another melanoma cell line (STU) with a BRAFV600K/NRASWT mutation signature were exposed for 72 h to increasing concentrations of dabrafenib (D), trametinib (T), MBZ, or combinations of T+D or T+MBZ.